References

Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis.

10.1016/s2213-2600(19)30198-5 · 2019 · External reference

Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study.

10.1016/s0140-6736(05)71141-7 · 2005 · External reference

Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort.

2008 · External reference

Treatment of adult obstructive sleep apnea with positive airway pressure: an American Academy of Sleep Medicine clinical practice guideline.

10.5664/jcsm.7640 · 2019 · External reference

Adherence to continuous positive airway pressure therapy: the challenge to effective treatment.

10.1513/pats.200708-119mg · 2008 · External reference

Interactions between obesity and obstructive sleep apnea: implications for treatment.

10.1378/chest.09-0360 · 2010 · External reference

Obesity and obstructive sleep apnea: pathogenic mechanisms and therapeutic approaches.

10.1513/pats.200708-137mg · 2008 · External reference

Defining phenotypic causes of obstructive sleep apnea. Identification of novel therapeutic targets.

10.1164/rccm.201303-0448oc · 2013 · External reference

Longitudinal study of moderate weight change and sleep-disordered breathing.

10.1001/jama.284.23.3015 · 2000 · External reference

CPAP, weight loss, or both for obstructive sleep apnea.

10.1056/nejmoa1306187 · 2014 · External reference

Obstructive sleep apnea without obesity is common and difficult to treat: evidence for a distinct pathophysiological phenotype.

10.5664/jcsm.6394 · 2017 · External reference

The relationship between obesity and obstructive sleep apnea in four community-based cohorts: an individual participant data meta-analysis of 12,860 adults.

10.1016/j.eclinm.2025.103221 · 2025 · External reference

FDA approves tirzepatide as first drug for obstructive sleep apnea.

10.1001/jama.2024.28055 · 2025 · External reference

Tirzepatide once weekly for the treatment of obesity.

10.1056/nejmoa2206038 · 2022 · External reference

10.1186/s41073-019-0064-8 · 2019 · Admitted local publication

Effect of liraglutide 3.0?mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.

10.1038/ijo.2016.52 · 2016 · External reference

Effect of weight loss on upper airway anatomy and the Apnea-Hypopnea Index: the importance of tongue fat.

10.1164/rccm.201903-0692oc · 2020 · External reference

Semaglutide reduces fat accumulation in the tongue: a randomized single-blind, pilot study.

10.1016/j.diabres.2021.108935 · 2021 · External reference

The effect of surgical weight loss on upper airway fat in obstructive sleep apnoea.

10.1007/s11325-022-02734-8 · 2023 · External reference

GABA neurons in the nucleus tractus solitarius express GLP-1 receptors and mediate anorectic effects of liraglutide in rats.

10.1126/scitranslmed.aay8071 · 2020 · External reference

A genetic map of the mouse dorsal vagal complex and its role in obesity.

10.1038/s42255-021-00363-1 · 2021 · External reference

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons.

10.1172/jci0215595 · 2002 · External reference

Pathophysiology of sleep apnea.

10.1152/physrev.00043.2008 · 2010 · External reference

Enhanced upper-airway muscle responsiveness is a distinct feature of overweight/obese individuals without sleep apnea.

10.1164/rccm.201404-0783oc · 2014 · External reference

Tirzepatide for the treatment of obstructive sleep apnea: rationale, design, and sample baseline characteristics of the SURMOUNT-OSA phase 3 trial.

10.1016/j.cct.2024.107516 · 2024 · External reference

Peripheral chemoreceptors: function and plasticity of the carotid body.

10.1002/j.2040-4603.2012.tb00399.x · 2012 · External reference

GLP1R attenuates sympathetic response to high glucose via carotid body inhibition.

10.1161/circresaha.121.319874 · 2022 · External reference

Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea.

10.1097/mcp.0000000000001208 · 2025 · External reference

Effect of weight loss on upper airway collapsibility in obstructive sleep apnea.

10.1164/ajrccm/144.3_pt_1.494 · 1991 · External reference

Neural control of breathing and CO2 homeostasis.

10.1016/j.neuron.2015.08.001 · 2015 · External reference

Localizing effects of leptin on upper airway and respiratory control during sleep.

10.5665/sleep.5762 · 2016 · External reference

Leptin-mediated neural targets in obesity hypoventilation syndrome.

10.1093/sleep/zsac153 · 2022 · External reference

Mechanisms of action and therapeutic application of glucagon-like peptide-1.

10.1016/j.cmet.2018.03.001 · 2018 · External reference

Leptin signaling in the dorsomedial hypothalamus couples breathing and metabolism in obesity.

10.1016/j.celrep.2023.113512 · 2023 · External reference

Intranasal leptin relieves sleep-disordered breathing in mice with diet-induced obesity.

10.1164/rccm.201805-0879oc · 2019 · External reference

Abnormalities in the genioglossus muscle and its neuromuscular synapse in leptin-deficient male mice.

10.1186/s13395-025-00387-1 · 2025 · External reference

Effects of obesity upon genioglossus structure and function in obstructive sleep apnoea.

10.1183/09031936.04.00099404 · 2004 · External reference

Inflammasome activation: a keystone of proinflammatory response in obstructive sleep apnea.

10.1164/rccm.202106-1445oc · 2022 · External reference

Effect of the NLRP3 inflammasome on increased hypoxic ventilation response after CIH exposure in mice.

10.1016/j.resp.2023.104204 · 2024 · External reference

GLP-1 alleviates NLRP3 inflammasome–dependent inflammation in perivascular adipose tissue by inhibiting the NF-?B signaling pathway.

10.1177/0300060521992981 · 2021 · External reference

GLP-1 analogue liraglutide attenuates CIH-induced cognitive deficits by inhibiting oxidative stress, neuroinflammation, and apoptosis via the Nrf2/HO-1 and MAPK/NF-?B signaling pathways.

10.1016/j.intimp.2024.113222 · 2024 · External reference

NADPH oxidase 2 is necessary for chronic intermittent hypoxia-induced sternohyoid muscle weakness in adult male mice.

10.1113/ep090536 · 2022 · External reference

Glucagon-like peptide-1 improves beta-cell antioxidant capacity via extracellular regulated kinases pathway and Nrf2 translocation.

10.1016/j.freeradbiomed.2016.03.002 · 2016 · External reference

GLP-1 receptor agonists, SGLT-2 inhibitors, and obstructive sleep apnoea: can new allies face an old enemy?

10.5114/amsad/161170 · 2023 · External reference

Tirzepatide for the treatment of obstructive sleep apnea and obesity.

10.1056/nejmoa2404881 · 2024 · External reference

Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: time course and association with body weight.

10.1016/j.sleep.2025.106853 · 2025 · External reference

Continuous positive airway pressure but not GLP1-mediated weight loss improves early cardiovascular disease in obstructive sleep apnea: a randomized proof-of-concept study.

10.1513/annalsats.202309-821oc · 2024 · External reference

Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis.

10.1093/sleep/zsae280 · 2025 · External reference

Safety and efficacy of glucagon-like peptide-1 receptor agonists in patients with obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials.

10.1080/20018525.2025.2484048 · 2025 · External reference

Glucagon-like peptide-1 receptor agonists for obstructive sleep apnea in patients with obesity and type 2 diabetes mellitus: a systematic review and meta-analysis.

10.1186/s12967-025-06302-y · 2025 · External reference

Efficacy and safety of GLP-1 receptor agonists in the management of obstructive sleep apnea in individuals without diabetes: a systematic review and meta-analysis of randomized, placebo-controlled trials.

10.1016/j.sleep.2025.02.010 · 2025 · External reference

Effect of sleep apnoea interventions on multiple health outcomes: an umbrella review of meta-analyses of randomised controlled trials.

10.1016/j.eclinm.2025.103529 · 2025 · External reference

The impact of glucagon-like peptide 1 receptor agonists on obstructive sleep apnoea: a scoping review.

10.3390/pharmacy12010011 · 2024 · External reference

Results of the ADHERE upper airway stimulation registry and predictors of therapy efficacy.

10.1002/lary.28286 · 2020 · External reference

Long-term trends in body mass index throughout upper airway stimulation treatment: does body mass index matter?

10.5664/jcsm.10496 · 2023 · External reference

Effect of parapharyngeal fat on dynamic obstruction of the upper airway in patients with obstructive sleep apnea.

10.1164/rccm.201408-1498le · 2014 · External reference

Predicting complete concentric collapse at the palatal level during drug-induced sleep endoscopy: an analysis of 1761 cases.

10.1007/s11325-024-03172-4 · 2024 · External reference

Cardiovascular effects and tolerability of GLP-1 receptor agonists: a systematic review and meta-analysis of 99,599 patients.

10.1016/j.jacc.2025.08.027 · 2025 · External reference

Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity.

10.1001/jamanetworkopen.2024.57349 · 2025 · External reference

Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes.

10.18553/jmcp.2024.23332 · 2024 · External reference

Anatomical balance of the upper airway and obstructive sleep apnea.

10.1097/aln.0b013e318173f103 · 2008 · External reference

Lifetime health effects and cost-effectiveness of tirzepatide and semaglutide in US adults.

10.1001/jamahealthforum.2024.5586 · 2025 · External reference